Baek; Yi Yong

Patent Applications and Registrations

Patent applications and USPTO patent grants for Baek; Yi Yong.The latest application filed is for "cytoplasmic transduction peptide and intracellular messenger comprising same".

Company Profile

5.5.11

Baek; Yi Yong - Goyang-si KR
BAEK; Yi Yong - Goyang-si Gyeonggi-do KR
BAEK; Yi Yong - Gyeonggi-do KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Peptide for inhibiting skin inflammation and composition for preventing or treating skin inflammation containing the same Grant 11,208,433 - Baek , et al. December 28, 2	2021-12-28
Cytoplasmic Transduction Peptide And Intracellular Messenger Comprising Same App 20210388029 - BAEK; Yi Yong ; et al.	2021-12-16
Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative Grant 11,141,407 - Kim , et al. October 12, 2	2021-10-12
Angiogenesis-inhibiting Peptide And Composition For Preventing And Treating Angiogenesis-related Disease Comprising Same As Active Ingredient App 20210292363 - KIM; Young Myeong ; et al.	2021-09-23
Pharmaceutical Composition Comprising Fusion Protein Of Cell-penetrating Peptide And Rpe65 For Treatment Of Leber's Congenital Amaurosis App 20210254037 - SHIN; Woo Ri ; et al.	2021-08-19
Fusion Protein Bound To Cell-permeable Peptide, Andcomposition Comprising Fusion Protein Or Cell-permeablepeptide And Epithelial Cell Growth Factor As Activeingredients App 20210251872 - BAEK; Yi Yong ; et al.	2021-08-19
Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient Grant 11,040,999 - Kim , et al. June 22, 2	2021-06-22
Pharmaceutical Composition For Treating Severe Complex Immunodeficiency Comprising Fusion Protein Of Cell Penetrating Peptide And Adenosine Deaminase App 20210106662 - JI; Eun Hye ; et al.	2021-04-15
Pharmaceutical Composition For Preventing Or Treating Aids Comprising Rhodanine Derivative App 20210000802 - KIM; Min Jung ; et al.	2021-01-07
Pharmaceutical composition for preventing or treating AIDS comprising rhodanine derivative Grant 10,821,101 - Kim , et al. November 3, 2	2020-11-03
Peptide For Inhibiting Skin Inflammation And Composition For Preventing Or Treating Skin Inflammation Containing The Same App 20200190141 - BAEK; Yi Yong ; et al.	2020-06-18
Pharmaceutical Composition For Preventing Or Treating Aids Comprising Rhodanine Derivative App 20190388399 - KIM; Min Jung ; et al.	2019-12-26
Cytoplasmic Transduction Peptide And Intracellular Messenger Comprising Same App 20190315809 - BAEK; Yi Yong ; et al.	2019-10-17
Improved Angiogenesis-inhibiting Peptide And Composition For Preventing And Treating Angiogenesis-related Disease Comprising Sam App 20190315803 - KIM; Young Myeong ; et al.	2019-10-17
Tetrapeptide having effect of inhibiting VEGF-induced angiogenesis and use thereof Grant 9,969,771 - Kim , et al. May 15, 2	2018-05-15
Tetrapeptide Having Effect Of Inhibiting Vegf-induced Angiogenesis And Use Thereof App 20170037083 - KIM; Young Myeong ; et al.	2017-02-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.